The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
Open accessAbstract
PEGylated gold nanoparticles are decorated with various amounts of human transferrin (Tf) to give a series of Tf-targeted particles with near-constant size and electrokinetic potential. The effects of Tf content on nanoparticle tumor targeting were investigated in mice bearing s.c. Neuro2A tumors. Quantitative biodistributions of the nanoparticles 24 h after i.v. tail-vein injections show that the nanoparticle accumulations in the tumors and other organs are independent of Tf. However, the nanoparticle localizations within a particular organ are influenced by the Tf content. In tumor tissue, the content of targeting ligands significantly influences the number of nanoparticles localized within the cancer cells. In liver tissue, high Tf content leads to small amounts of the nanoparticles residing in hepatocytes, whereas most nanoparticles remain in nonparenchymal cells. These results suggest that targeted nanoparticles can provide greater intracellular delivery of therapeutic agents to the cancer cells within solid tumors than their nontargeted analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions
FRENS, G. (1973) · Nature Physical Science · doi:10.1038/physci241020a0 · Cited by 8,336
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“T nanoparticle delivery of therapeutic molecules has the potential to provide safer and more effective therapies for cancer applications (1).”
BackgroundSelf-citationNanoparticle-mediated cellular response is size-dependent
Jiang, W., Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.30 · Cited by 2,776
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
De Jong, W. H., Hagens, W. I., Krystek, P., Burger, M. C., Sips, A. J. A. M., & Geertsma, R. E. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.037 · Cited by 1,615
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,513
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Self-citationAnti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Danscher, G. (1981) · Histochemistry · doi:10.1007/bf00592566 · Cited by 746
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Self-citationThomas, M., & Klibanov, A. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1233634100 · Cited by 549
Transferrin receptors in human tissues: their distribution and possible clinical relevance.
Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R. E., & Mason, D. Y. (1983) · Journal of Clinical Pathology · doi:10.1136/jcp.36.5.539 · Cited by 531
Multivalent Effects of RGD Peptides Obtained by Nanoparticle Display
Montet, X., Funovics, M., Montet-Abou, K., Weissleder, R., & Josephson, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060515m · Cited by 388
Ishida, O., Maruyama, K., Tanahashi, H., Iwatsuru, M., Sasaki, K., Eriguchi, M., & Yanagie, H. (2001) · Pharmaceutical Research · doi:10.1023/a:1010960900254 · Cited by 257
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
de Menezes, D. E. L., Pilarski, L. M., & Allen, T. M. (1998) · PubMed · Cited by 257
Bhattacharya, R., Patra, C. R., Earl, A., Wang, S., Katarya, A., Lu, L., Kizhakkedathu, J. N., Yaszemski, M. J., Greipp, P. R., Mukhopadhyay, D., et al. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2007.07.001 · Cited by 200
Zhou, Y., Drummond, D. C., Zou, H., Hayes, M. E., Adams, G. P., Kirpotin, D. B., & Marks, J. D. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.011 · Cited by 151
Yang, M., Yau, H. C. M., & Chan, H. L. (1998) · Langmuir · doi:10.1021/la980577i · Cited by 126
Sawyer, S. T., & Krantz, S. B. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67637-9 · Cited by 82
Popielarski, S. R., Pun, S. H., & Davis, M. E. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050113d · Cited by 81
Self-citationEnns, C. A., Rutledge, E. A., & Williams, A. M. (1996) · Biomembranes · doi:10.1016/s1874-5342(96)80012-2 · Cited by 37
Peptide mapping of the human transferrin receptor in normal and transformed cells.
Stein, B., & Sussman, H. H. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32978-8 · Cited by 25
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,633
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Gold nanoparticles in biomedical applications: recent advances and perspectives
Dykman, L., & Khlebtsov, N. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15166e · Cited by 1,961
Metadata
- Authors
- Choi, C. H. J., Alabi, C. A., Webster, P., & Davis, M. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-12-29
- Volume
- 107
- Issue
- 3
- Pages
- 1235-1240
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2006165138
- Cited by
- 699
- References
- 26
- FWCI
- 16.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.